Nisa Investment Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 30.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,500 shares of the biopharmaceutical company’s stock after buying an additional 1,500 shares during the period. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $447,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ALNY. Dimensional Fund Advisors LP raised its position in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock worth $4,170,000 after buying an additional 695 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock worth $2,755,000 after buying an additional 7,048 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 1,614 shares in the last quarter. Bank of Montreal Can raised its position in shares of Alnylam Pharmaceuticals by 283.6% in the first quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 7,044 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Alnylam Pharmaceuticals by 11.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 67,000 shares of the biopharmaceutical company’s stock worth $3,434,000 after buying an additional 7,000 shares in the last quarter. Institutional investors own 88.96% of the company’s stock.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded up 2.49% during mid-day trading on Friday, reaching $77.83. 350,909 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $81.11 and a 200-day moving average price of $61.63. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The stock’s market cap is $6.86 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 48.01% and a negative net margin of 670.81%. The business had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. During the same quarter last year, the firm earned ($1.05) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.23) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Position Boosted by Nisa Investment Advisors LLC” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/11/alnylam-pharmaceuticals-inc-alny-position-boosted-by-nisa-investment-advisors-llc.html.

A number of research analysts have recently commented on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $56.00 price objective (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Chardan Capital reaffirmed a “buy” rating and set a $124.00 price objective (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an “equal weight” rating in a research report on Thursday. Barclays PLC upped their price objective on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $81.74.

In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the sale, the vice president now owns 5,625 shares in the company, valued at approximately $393,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Akshay Vaishnaw sold 11,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the completion of the sale, the executive vice president now owns 21,297 shares of the company’s stock, valued at approximately $1,597,275. The disclosure for this sale can be found here. Insiders sold a total of 64,125 shares of company stock valued at $4,325,000 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.